MS Clinical Care Connection |
FDA Approves Ocrevus™ for People with Primary Progressive MS or Relapsing MS: |
The Food and Drug Administration has approved Ocrevus™ (ocrelizumab - Genentech, a member of the Roche Group) for use in the treatment of primary progressive MS and relapsing MS, making it the first disease-modifying therapy for primary progressive MS. National MS Society announcement and FAQ
What is Ocrevus
Ocrevus is a monoclonal antibody that depletes the number of B-cells circulating in the blood by binding to a molecule (CD20) on the surface of the cells. The medication is administered by intravenous infusion every 6 months.
Trial details and more information
The New England Journal of Medicine December 2016:
|
Newly Updated MS Coalition Paper: |
The Use of Disease-Modifying Therapies in MS Read the full consensus paper on the principles and current evidence and accompanying summary for general audiences by the Multiple Sclerosis Coalition.
|
New Social Security Guidebook for Clinicians and their Patients:
|
The Social Security Administration has updated the criteria for neurologic conditions, including MS. This Guidebook provides you and your patients the information and tools you need to file a successful disability application.
|
Wellness Webinars and Resources to Help Your Practice:
|
Free CME and CE
|
Download the Free App
Information at your fingertips about MS diagnosis, disease and symptom management.iPhone or Android |
The National MS Society supports MS healthcare professionals through professional publications, tools and materials, as well as resources to share with patients and their families. Our information and resources are designed to help people affected by MS live their best lives — in partnership with all of the members of the MS comprehensive healthcare team. |